Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis

Timothy L Comstock1, Paul M Karpecki2, Timothy W Morris3, Jin-Zhong Zhang41Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA; 2Koffler Vision Group, Lexington, KY, USA; 3Research and Development Microbiology and Sterilization Sciences, Bausch and Lomb, Inc., Rocheste...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Timothy L Comstock, Paul M Karpecki, Timothy W Morris, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/558707f1c679417aa2490cd37df17be9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:558707f1c679417aa2490cd37df17be9
record_format	dspace
spelling	oai:doaj.org-article:558707f1c679417aa2490cd37df17be92021-12-02T08:31:37ZBesifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis1177-54671177-5483https://doaj.org/article/558707f1c679417aa2490cd37df17be92010-03-01T00:00:00Zhttp://www.dovepress.com/besifloxacin-a-novel-anti-infective-for-the-treatment-of-bacterial-con-a4152https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Timothy L Comstock1, Paul M Karpecki2, Timothy W Morris3, Jin-Zhong Zhang41Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA; 2Koffler Vision Group, Lexington, KY, USA; 3Research and Development Microbiology and Sterilization Sciences, Bausch and Lomb, Inc., Rochester, NY, USA; 4Global Preclinical Development, Bausch and Lomb, Inc., Rochester, NY, USAAbstract: Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is critical in preventing potentially irreversible ocular damage. However, the rise in ocular methicillin-resistant Staphylococcus aureus isolates and the patterns of fluoroquinolone resistance for patients with other ocular bacterial infections mandate the need for new agents targeted for ocular use. Besifloxacin, a novel broad-spectrum fluoroquinolone, is approved for the treatment of bacterial conjunctivitis. It has a uniquely balanced dual-targeting activity that inhibits both DNA gyrase and topoisomerase IV and is associated with a lower incidence of resistance development. Besifloxacin is not marketed in other formulations, ensuring that its exposure is limited to bacterial populations in and around the eye. This specifically precludes any bacterial exposure to besifloxacin resulting from systemic use, which further reduces the likelihood of emergence of bacterial resistance. In vitro, besifloxacin has demonstrated equivalent or superior activity compared with other commonly used topical antibiotics. In clinical trials, besifloxacin has consistently demonstrated efficacy and safety in the treatment of patients with bacterial conjunctivitis. Besifloxacin is considered safe and is well tolerated with no observed contraindications.Keywords: conjunctivitis, fluoroquinolones, besifloxacin, besivance, bacterial conjunctivitis Timothy L ComstockPaul M KarpeckiTimothy W Morriset alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 215-225 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Timothy L Comstock Paul M Karpecki Timothy W Morris et al Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
description	Timothy L Comstock1, Paul M Karpecki2, Timothy W Morris3, Jin-Zhong Zhang41Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA; 2Koffler Vision Group, Lexington, KY, USA; 3Research and Development Microbiology and Sterilization Sciences, Bausch and Lomb, Inc., Rochester, NY, USA; 4Global Preclinical Development, Bausch and Lomb, Inc., Rochester, NY, USAAbstract: Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is critical in preventing potentially irreversible ocular damage. However, the rise in ocular methicillin-resistant Staphylococcus aureus isolates and the patterns of fluoroquinolone resistance for patients with other ocular bacterial infections mandate the need for new agents targeted for ocular use. Besifloxacin, a novel broad-spectrum fluoroquinolone, is approved for the treatment of bacterial conjunctivitis. It has a uniquely balanced dual-targeting activity that inhibits both DNA gyrase and topoisomerase IV and is associated with a lower incidence of resistance development. Besifloxacin is not marketed in other formulations, ensuring that its exposure is limited to bacterial populations in and around the eye. This specifically precludes any bacterial exposure to besifloxacin resulting from systemic use, which further reduces the likelihood of emergence of bacterial resistance. In vitro, besifloxacin has demonstrated equivalent or superior activity compared with other commonly used topical antibiotics. In clinical trials, besifloxacin has consistently demonstrated efficacy and safety in the treatment of patients with bacterial conjunctivitis. Besifloxacin is considered safe and is well tolerated with no observed contraindications.Keywords: conjunctivitis, fluoroquinolones, besifloxacin, besivance, bacterial conjunctivitis
format	article
author	Timothy L Comstock Paul M Karpecki Timothy W Morris et al
author_facet	Timothy L Comstock Paul M Karpecki Timothy W Morris et al
author_sort	Timothy L Comstock
title	Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
title_short	Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
title_full	Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
title_fullStr	Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
title_full_unstemmed	Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
title_sort	besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/558707f1c679417aa2490cd37df17be9
work_keys_str_mv	AT timothylcomstock besifloxacinanovelantiinfectiveforthetreatmentofbacterialconjunctivitis AT paulmkarpecki besifloxacinanovelantiinfectiveforthetreatmentofbacterialconjunctivitis AT timothywmorris besifloxacinanovelantiinfectiveforthetreatmentofbacterialconjunctivitis AT etal besifloxacinanovelantiinfectiveforthetreatmentofbacterialconjunctivitis
_version_	1718398483725025280

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis

Ejemplares similares